Scott Hutton Sells 83,660 Shares of Biodesix, Inc. (NASDAQ:BDSX) Stock

Biodesix, Inc. (NASDAQ:BDSX) CEO Scott Hutton sold 83,660 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the sale, the chief executive officer now directly owns 701,947 shares of the company’s stock, valued at $645,791.24. The trade was a 10.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Biodesix Price Performance

NASDAQ BDSX traded down $0.01 on Wednesday, reaching $0.94. The company’s stock had a trading volume of 170,859 shares, compared to its average volume of 460,809. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. Biodesix, Inc. has a twelve month low of $0.86 and a twelve month high of $2.04. The stock has a market cap of $136.74 million, a PE ratio of -2.41 and a beta of 1.06. The firm’s 50 day moving average is $1.26 and its two-hundred day moving average is $1.49.

Institutional Trading of Biodesix

Hedge funds have recently bought and sold shares of the company. Barclays PLC lifted its stake in Biodesix by 1,140.5% during the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock valued at $41,000 after buying an additional 21,179 shares in the last quarter. HighTower Advisors LLC lifted its stake in Biodesix by 17.1% during the fourth quarter. HighTower Advisors LLC now owns 153,934 shares of the company’s stock valued at $236,000 after buying an additional 22,500 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Biodesix during the third quarter valued at about $262,000. Stephens Inc. AR purchased a new stake in Biodesix during the fourth quarter valued at about $303,000. Finally, Geode Capital Management LLC lifted its stake in Biodesix by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 827,199 shares of the company’s stock valued at $1,266,000 after buying an additional 22,623 shares in the last quarter. 20.96% of the stock is owned by hedge funds and other institutional investors.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.